Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:ALVR NASDAQ:LONA NASDAQ:ONCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$4.51+5.1%$4.82$3.35▼$17.94$93.59M5.11164,812 shs166,493 shsALVRAlloVir$4.83+2.8%$6.17$7.96▼$24.15$24.36M0.6315,685 shs53,234 shsLONAAthira Pharma$10.07+4.7%$9.56$2.61▼$14.21$90.37M1.9834,005 shs193,237 shsONCYOncolytics Biotech$0.79-3.7%$0.95$0.33▼$1.51$97.87M1.021.26 million shs355,792 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+5.13%-32.99%-16.01%-63.39%-59.44%ALVRAlloVir+2.77%0.00%-26.82%-56.01%+45.05%LONAAthira Pharma+4.68%-8.45%+9.22%+81.12%+1,006,999,900.00%ONCYOncolytics Biotech-3.66%-9.50%-29.46%-18.05%+87.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$4.51+5.1%$4.82$3.35▼$17.94$93.59M5.11164,812 shs166,493 shsALVRAlloVir$4.83+2.8%$6.17$7.96▼$24.15$24.36M0.6315,685 shs53,234 shsLONAAthira Pharma$10.07+4.7%$9.56$2.61▼$14.21$90.37M1.9834,005 shs193,237 shsONCYOncolytics Biotech$0.79-3.7%$0.95$0.33▼$1.51$97.87M1.021.26 million shs355,792 shsThe 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+5.13%-32.99%-16.01%-63.39%-59.44%ALVRAlloVir+2.77%0.00%-26.82%-56.01%+45.05%LONAAthira Pharma+4.68%-8.45%+9.22%+81.12%+1,006,999,900.00%ONCYOncolytics Biotech-3.66%-9.50%-29.46%-18.05%+87.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$19.70336.81% UpsideALVRAlloVir 0.00N/AN/AN/ALONAAthira Pharma 2.25Hold$10.00-0.70% DownsideONCYOncolytics Biotech 2.75Moderate Buy$8.50975.95% UpsideCurrent Analyst Ratings BreakdownLatest ALVR, ONCY, LONA, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.005/15/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.005/13/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026LONAAthira Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/24/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)3/27/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026ONCYOncolytics Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$3.99 per shareN/AALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/ALONAAthira PharmaN/AN/AN/AN/A$5.25 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A($0.04) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/AALVRAlloVir-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/ALONAAthira Pharma-$105.61M-$5.21N/AN/AN/AN/A-381.01%-225.74%N/AONCYOncolytics Biotech-$28.76M-$0.31N/AN/AN/AN/A-14,442.84%-321.54%7/31/2026 (Estimated)Latest ALVR, ONCY, LONA, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ONCYOncolytics Biotech-$0.05-$0.08-$0.03-$0.08N/AN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A5/7/2026Q1 2026LONAAthira PharmaN/A-$1.73N/A-$1.73N/AN/A3/31/2026Q4 2025ONCYOncolytics Biotech-$0.06-$0.08-$0.02-$0.08N/AN/A3/26/2026Q4 2025LONAAthira PharmaN/A-$18.90N/A-$18.90N/AN/A3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/ALONAAthira PharmaN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06ALVRAlloVirN/A86.7886.78LONAAthira PharmaN/A10.3810.38ONCYOncolytics BiotechN/A1.381.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AALVRAlloVir66.05%LONAAthira Pharma57.12%ONCYOncolytics Biotech6.82%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AALVRAlloVir32.07%LONAAthira Pharma25.73%ONCYOncolytics Biotech0.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/AALVRAlloVir1105.04 million3.43 millionNo DataLONAAthira Pharma409.39 million6.98 millionN/AONCYOncolytics Biotech30119.35 million119.24 millionNot OptionableALVR, ONCY, LONA, and AARD HeadlinesRecent News About These CompaniesONCY: Aligns with FDA on pivotal trial for Pelareorep in anal cancerMay 19 at 6:36 PM | msn.comOncolytics Biotech (NASDAQ:ONCY) Stock Rating Lowered by Wall Street ZenMay 16, 2026 | americanbankingnews.comOncolytics Biotech (ONCY) to Release Quarterly Earnings on WednesdayMay 11, 2026 | americanbankingnews.comOncolytics Biotech (ONCY) Projected to Post Quarterly Earnings on WednesdayMay 6, 2026 | marketbeat.comOncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal CancerMay 4, 2026 | globenewswire.comOncolytics Biotech Inc. (NASDAQ:ONCY) Given Average Rating of "Moderate Buy" by AnalystsMay 1, 2026 | marketbeat.comOncolytics Biotech, Inc.: Oncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyApril 27, 2026 | finanznachrichten.deOncolytics Aligns with FDA on Planned Pivotal Anal Cancer StudyApril 27, 2026 | globenewswire.comOncolytics Could Re-Rate As Pelareorep Focuses On Registrational PathsApril 25, 2026 | seekingalpha.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: ArriVent BioPharma, Inc. (AVBP) and Oncolytics Biotech (ONCY)April 12, 2026 | theglobeandmail.comOncolytics Plans FDA Meeting for Pelareorep SCAC StudyApril 7, 2026 | theglobeandmail.comONCY: Initiating Coverage of Oncolytics Biotech; A Focused Path to Unlocking the Potential of PelareorepApril 7, 2026 | msn.comOncolytics Biotech Establishes $75 Million ATM OfferingApril 6, 2026 | tipranks.comOncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal CancerApril 6, 2026 | globenewswire.comOncolytics Biotech’s Nevada Move Resets Capital Access And Dilution Trade OffApril 1, 2026 | finance.yahoo.comOncolytics Biotech® Completes Domicile Change to the United StatesApril 1, 2026 | globenewswire.comThe Patent Cliff is Coming, Driving Smart Money Towards Precision OncologyMarch 19, 2026 | financialpost.comFOncolytics Biotech® to Present New Mechanistic and Translational Data Supporting Pelareorep as an Immune-Priming Backbone at AACR 2026March 19, 2026 | globenewswire.comJames Parsons Acquires 10,000 Shares of Oncolytics Biotech (NASDAQ:ONCY) StockMarch 14, 2026 | insidertrades.comCancer Treatment Breakthroughs Stack Up as Clinical Pipelines AdvanceMarch 4, 2026 | baystreet.caOncolytics Biotech® Launches Randomized Colorectal Cancer StudyMarch 2, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALVR, ONCY, LONA, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$4.51 +0.22 (+5.13%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$4.55 +0.04 (+0.82%) As of 06:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.AlloVir NASDAQ:ALVR$4.83 +0.13 (+2.77%) As of 05/20/2026AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Athira Pharma NASDAQ:LONA$10.07 +0.45 (+4.68%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$10.08 +0.01 (+0.11%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.Oncolytics Biotech NASDAQ:ONCY$0.79 -0.03 (-3.66%) Closing price 05/21/2026 04:00 PM EasternExtended Trading$0.82 +0.02 (+3.16%) As of 07:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
